albuvirtide + 3BNC117

albuvirtide + 3BNC117 is an investigational, all-injectable, long-acting two-drug regimen for the treatment and maintenance therapy of HIV-1 infection in virologically suppressed or multi-drug resistant patients. **Albuvirtide (ABT)** is a long-acting HIV-1 fusion inhibitor that binds to the gp41 subunit of the HIV envelope glycoprotein, preventing viral fusion with host cells. **3BNC117** is a broadly neutralizing monoclonal antibody (bNAb) that targets the CD4 binding site of the HIV-1 envelope glycoprotein gp120, thereby blocking viral entry and neutralizing diverse HIV-1 strains. The combination is designed as a maintenance or salvage therapy that may offer an alternative to daily oral antiretroviral therapy, aiming to reduce resistance development and improve adherence by utilizing different molecular mechanisms. It is currently in phase 2 trials, with Frontier Biotechnologies as the main developer[1][3][5].